Apnimed, Inc. (APMD)
NASDAQ: APMD · Real-Time Price · USD
17.83
-0.80 (-4.29%)
Oct 13, 2026, 4:00 PM EDT - Market closed
Company Description
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Apnimed, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 31, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Kevin Lind |
Contact Details
Address: 39 John F. Kennedy Street, 4th Floor Cambridge, Massachusetts 02138 United States | |
| Phone | 617 500 8880 |
| Website | apnimed.com |
Stock Details
| Ticker Symbol | APMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1745648 |
| CUSIP Number | 03770Y107 |
| ISIN Number | US03770Y1073 |
| Employer ID | 82-1910611 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin Robert Lind | Chief Executive Officer and Director |
| Dr. Lawrence G. Miller M.D., M.P.H. | Founder and Vice Chair of the Board |
| Dennis Patrick Molnar M.B.A. | President and Chief Operating Officer |
| Dr. Luigi Taranto Montemurro M.D. | Co-Founder and Chief Scientific Officer |
| Michael B. Kelly | Chief Financial Officer |
| Leila Sylvain | Senior Manager of Administration |
| Steven W. Spector J.D. | Chief Legal Officer and Head of Corporate Affairs |
| Jennifer Patterson | Senior Vice President of Human Resources |
| Dr. John W. Cronin M.D. | Chief Medical Officer |
| Dr. Sean M. Johnston M.B.A., Ph.D. | Consulting Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 8, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 8, 2026 | 10-Q | Quarterly Report |
| Sep 8, 2026 | 8-K | Current Report |
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 6, 2026 | SCHEDULE 13G | Filing |
| Aug 3, 2026 | 8-K | Current Report |
| Jul 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 31, 2026 | 424B4 | Prospectus |
| Jul 30, 2026 | EFFECT | Notice of Effectiveness |
| Jul 30, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |